We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Genosis | GNOS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.125 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.125 | 1.125 |
| Top Posts |
|---|
Posted at 16/4/2007 11:44 by 68steve HH,read the RNS,yes old and new investors will be raising funds and soon,DYOR. |
Posted at 16/4/2007 10:09 by 68steve Does look interesting + old and new investors want in,as good as ground floor also... |
Posted at 16/4/2007 07:42 by lord santafe Genosis Signs up Major US retailerRNS Number:8715U Genosis PLC 16 April 2007 For Immediate Release 16 April 2007 Genosis PLC Signs up major US retailer CVS to sell its fertility test "Fertell" "Genosis' first step into the US" Genosis PLC, AIM:(GNOS) a company focusing on consumer products for reproductive health, is pleased to announce that from this May, CVS, the largest drug store chain in the United States will be selling, for the first time, its male and female OTC fertility test Fertell. CVS is the largest chain drug store in the US with over 6,000 stores across 43 states. Fertell will be sold through a combination of "on shelf" product, shelf cards promoting Fertell and at www.cvs.com. The Company has received an initial order from CVS which will be delivered to the CVS regional distribution centres in late April. Selling Fertell through CVS is the first step of Genosis' US distribution strategy. Genosis anticipates that during this year, additional distribution will be made with other chain drug and retail stores for them also to include the Fertell product as part of their fertility merchandising programmes. The Fertell couple test is ideally suited for the US market. Each year, in the US, it is estimated that there are over three million couples aged 25 to 40 that are trying to conceive. At-home fertility screening is an important and logical first step for couples who want more information about their fertility status. Fertell is the only FDA cleared OTC fertility test for couples and will typically retail for $99.99. Genosis plans to invest around $5 million on its US marketing launch campaign in 2007. US consumers will be alerted as to the availability and benefits of Fertell through print advertising, web media and PR. In addition to selling Fertell through chain drug stores the product is now available through www.fertell.com. In order to exploit and accelerate the opportunity in this highly significant US market, the Directors' believe that further funds are required. These funds will principally be utilised to support the marketing campaign of the Fertell product in the US. The Directors' are in the process of securing further financing and have already received informal commitments from a number of institutions, including both existing shareholders and new investors. An announcement will be made in the near future with regards to this financing which will be conditional on the approval of shareholders at an Extraordinary General Meeting and any necessary regulatory approval. It is anticipated that a notice of EGM will be dispatched to shareholders as soon as possible. Paul Batemen, Chief Executive Officer said: "The introduction of the Fertell product through CVS stores is a very significant milestone for the Company and a strong reflection of the market opportunity for at-home fertility testing. This fundraising will help us make the most of the sales potential for our innovative product in the key US market." For further details please contact: Genosis PLC Paul Bateman, CEO +44 (0)1483 774 051 Jonathan Pockson, CFO Buchanan Communications Lisa Baderoon +44 (0)20 7466 5000 Rebecca Skye Dietrich This information is provided by RNS The company news service from the London Stock Exchange END MSCMGGMDNFMGNZM |
Posted at 21/6/2006 13:01 by bruce the goldfish Well there goes the reason for the significant fall in the shareprice today. Someone sold 227k shares at 10p. At the current mid-price there does not appear to be much investor appetite for these so expect the shares to drift closer to that 10p sell price over the coming days/weeks. If the seller has still not finished offloading who knows where these could end up.Jon - cash of £5 million at 31 May 2006 was announced in AGM and trading update on 8th June. Personally feel that there is only limited value in Genesis at current levels. May be interested as a speculative gamble on the technology at prices sub-10p. Will just watch and wait for the time being... BTG |
Posted at 24/2/2006 12:23 by vantheman International Biotechnology TrustBy Ellen Kelleher in London Unlisted biotechnology companies offer opportunities for investors simply because they might be acquired or go public, Andy Smith, manager of the International Biotechnology Trust, says. His fund's exposure to unquoted companies distinguishes it from similar funds in the biotechnology sector. "One of the key drivers of performance is pharmaceutical companies buying smaller ones," Smith says. The fund targets undervalued companies with strong management, interest from investors and solid pipelines of products. But Mr Smith shies away from investing in smaller private companies. "We won't do every investment. We'll only do later-stage investments," he says. About 70 per cent of the trust, which has a portfolio of just 46 companies, is invested in public companies and about 30 per cent in private ones. About 60 per cent of its exposure is in US stocks. In Mr Smith's opinion, it is more important to figure out how to avoid investing in losers than picking winners. "The failure or success of biotechnology companies rests on clinical trials or drugs in the pipeline," he says. "If the company doesn't deliver a product, its fortunes suffer radically. Every time we make an investment, we have to look at where the pipeline is." Though Mr Smith is willing to invest anywhere in the world, the trust's top quoted investments at present are US biotech groups: Solexa, Genosis, Progenics Pharmaceuticals, ANorMed, Cambridge Antibody Tech, OSI Pharmaceuticals, Alexion Pharmaceuticals, Sunesis, Barr Pharmaceuticals and the Austrian biotech group CSL. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
